tetrahydropyran-4-yl-acrylic acid ethyl ester | 99228-16-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tetrahydropyran-4-yl-acrylic acid ethyl ester
• 英文别名: ethyl 1-(4-tetrahydropyranyl)eth-1-ene-2-carboxylate；ethyl 3-(tetrahydro-2H-pyran-4-yl)-2-propenoate；ethyl 3-(oxan-4-yl)prop-2-enoate
• CAS: 99228-16-7
• 化学式: C₁₀H₁₆O₃
• 分子量: 184.235
• InChiKey: LLRZTGSOBOFVQO-UHFFFAOYSA-N

物化性质

• 沸点：
  274.4±15.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tetrahydropyran-4-yl-acrylic acid ethyl ester 在 palladium on activated charcoal 硫酸 、 氢气 、 sodium ethanolate 、 lithium chloride 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 ethyl 2-oxo-4-(3,4,5,6-tetrahydro-2H-pyran-4-yl)butyrate
  参考文献：
  名称：

  Synthesis and angiotensin converting enzyme inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. I.

  摘要：

  新型血管紧张素转化酶（ACE）抑制剂的设计与合成，包括(R)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯硫氮杂环-5-乙酸（7, 26, 33 和 37）以及(S)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯氧氮杂环-5-乙酸（8 和 27），本文进行了描述。这些系列中的一些化合物在体外和体内显示出强烈的ACE抑制活性。同时讨论了结构-活性关系。

  DOI：

  10.1248/cpb.34.1128
• 作为产物：
  描述：

  4-醛基四氢吡喃 、 磷酰基乙酸三乙酯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 生成 tetrahydropyran-4-yl-acrylic acid ethyl ester
  参考文献：
  名称：

  通过镍亲核硅与烯丙醇的镍催化交叉偶联合成烯丙基硅烷。

  摘要：

  进行了NiCl2（PMe3）2催化的烯丙醇与甲硅烷基锌试剂（包括PhMe2SiZnCl，Ph2MeSiZnCl和Ph3SiZnCl）的反应，以高收率获得了烯丙基硅烷。芳基和杂芳基取代的烯丙醇，（E）-3-芳基丙-2-烯-1-醇，1-芳基丙-2-烯-1-醇和（E）-1-苯基戊-1-醇en-3-ol可用于转化。容许一定范围的官能团以及杂芳基。当使用1-或3-芳基取代的烯丙醇作为底物时，反应表现出高的区域选择性和E / Z-选择性。手性烯丙醇（S，E）-1-苯基戊-1-烯-3-醇的反应生成构型反转产物（R，E）-二甲基（苯基）（1-苯基戊-1-烯-3） -基）硅烷。

  DOI：

  10.1021/acs.orglett.9b02946

文献信息

• HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150259343A1

  公开（公告）日：2015-09-17

  The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及携带环状取代基的三环六氢二氮杂喹啉类化合物，以及生产它们的方法，含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的方法，以及制备这类化合物和组合物的方法。
• Preparation of 1-(4-tetrahydropyranyl)- or
  申请人：BASF Aktiengesellschaft

  公开号：US05221753A1

  公开（公告）日：1993-06-22

  A process for the preparation of 1-(4-tetrahydropyranyl)- or 1-(4-tetrahydrothiopyranyl)prop-1-en-3-ones of the general formula I ##STR1## where R.sup.1 is hydrogen, C.sub.1 - to C.sub.10 -alkyl, C.sub.1 - to C.sub.10 -alkoxy or aryloxy, R.sup.2 is hydrogen, C.sub.1 - to C.sub.4 -alkyl, or aryl which is unsubstituted or substituted by C.sub.1 - to C.sub.4 -alkyl and/or halogen, and X is oxygen or sulfur, by reacting 1-aminoprop-1-en-3-ones of the general formula II ##STR2## where R.sup.1 and R.sup.2 are as defined above, and R.sup.3 and R.sup.4, independently of one another, are hydrogen, C.sub.1 - to C.sub.4 -alkyl, aryl or together are a C.sub.2 - to C.sub.7 -alkylene chain, with a 4-tetrahydropyranyl- or 4-tetrahydrothiopyranylmagnesium halide of the general formula III ##STR3## where X is as defined above and Y is halogen, at from -20.degree. to 100.degree. C., and novel 1-(4-tetrahydropyranyl)- or 1-(4-tetrahydrothiopyranyl)prop-1-en-3-ones are described.

  一种制备通式I中1-(4-四氢吡喃基)-或1-(4-四氢硫代吡喃基)丙-1-烯-3-酮的方法，其中R.sup.1为氢、C.sub.1-至C.sub.10-烷基、C.sub.1-至C.sub.10-烷氧基或芳基，R.sup.2为氢、C.sub.1-至C.sub.4-烷基或未取代或被C.sub.1-至C.sub.4-烷基和/或卤素取代的芳基，X为氧或硫，通过将通式II中R.sup.1和R.sup.2定义如上所述，R.sup.3和R.sup.4分别为氢、C.sub.1-至C.sub.4-烷基、芳基或一起是C.sub.2-至C.sub.7-烷基链的1-氨基丙-1-烯-3-酮与通式III中X如上定义，Y为卤素的4-四氢吡喃基-或4-四氢硫代吡喃基镁卤化物在-20°C至100°C反应，描述了新型的1-(4-四氢吡喃基)-或1-(4-四氢硫代吡喃基)丙-1-烯-3-酮。
• Intermediates for the preparation of condensed seven-membered ring
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04739066A1

  公开（公告）日：1988-04-19

  Novel condensed seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 and R.sup.5 are independently hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or lower alkyl; R.sup.6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

  这是一种化合物的化学式：##STR1## [其中R.sup.1和R.sup.2分别为氢、卤素、三氟甲基、低碳基或低碳氧基，或共同形成三亚甲基或四亚甲基；R.sup.3和R.sup.5分别为氢、低碳基或芳基低碳基；R.sup.4为氢或低碳基；R.sup.6为含有至少一个N、O和S原子作为环形成原子的紧缩或非紧缩杂环，可以被取代；A是一个烷基链；n为1或2]和它们的盐。这些化合物表现出对血管紧张素转换酶等的抑制活性，并且作为诊断、预防和治疗循环系统疾病（如高血压、心脏病和脑中风）的药物具有价值。
• 3-Amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04548932A1

  公开（公告）日：1985-10-22

  Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R.sup.4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).

  化合物及其盐，其结构式为##STR1##[其中，R.sup.1和R.sup.2独立地为氢、卤素、三氟甲基、较低的烷基或较低的烷氧基，或共同形成三亚甲基或四亚甲基; R.sup.3为氢、可选取代的较低烷基或可选取代的芳基烷基; R.sup.4为氢、可选取代的烷基、可选取代的芳基烷基或可选取代的环烷基烷基; Y为羧基，可以酯化或酰胺化; m为1或2]。这些化合物及其盐表现出对血管紧张素转换酶等的抑制活性，因此具有作为循环疾病（如高血压、心脏病、脑中风）的诊断、预防和治疗剂的价值。
• 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04591458A1

  公开（公告）日：1986-05-27

  Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R.sup.4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).

  化合物和盐的新颖3-氨基-4-氧代-2,3,4,5-四氢-1,5-苯并噁唑衍生物的公式为##STR1##[其中R.sup.1和R.sup.2独立地为氢，卤素三氟甲基，低级烷基或低级烷氧基，或共同形成三亚甲基或四亚甲基; R.sup.3为氢，可选择取代的低级烷基或可选择取代的芳基烷基; R.sup.4为氢，可选择取代的烷基，可选择取代的芳基烷基或可选择取代的环烷基烷基; Y为可酯化或酰胺化的羧基; m为1或2]。这些化合物及其盐表现出对血管紧张素转换酶等的抑制活性，并具有作为循环疾病（如高血压，心脏病，脑卒中）的诊断，预防和治疗剂的价值。